1h Free Analyst Time
The neuropathy pain treatment market is forecasted to grow by USD 5.84 billion during 2023-2028, accelerating at a CAGR of 10.96% during the forecast period. The report on the neuropathy pain treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the presence of a large patient pool of neuropathy pain, a growing focus on the development of drugs for the treatment of diabetic neuropathy pain, and rising penetration of generic drugs.
The neuropathy pain treatment market is segmented as below:
By Indication
- Diabetic neuropathy
- Chemotherapy-induced neuropathy pain
- Postherpetic neuralgia
- Others
By Distribution Channel
- Retail pharmacies
- Hospital pharmacies
- Online pharmacies
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the neuropathy pain treatment market covers the following areas:
- Neuropathy pain treatment market sizing
- Neuropathy pain treatment market forecast
- Neuropathy pain treatment market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Indication
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global neuropathy pain treatment market: Abbott Laboratories, Alfasigma Spa, Astellas Pharma Inc., AstraZeneca Plc, Baxter International Inc., Biogen Inc., Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., Eli Lilly and Co., Endo International Plc, GlaxoSmithKline Plc, Johnson and Johnson, Mallinckrodt Plc, Neuracle Lifesciences Pvt. Ltd., Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Inc., and VistaGen Therapeutics Inc.Commenting on the report, an analyst from the publisher said: 'The latest trend gaining momentum in the market is the development of topical patches for neuropathy pain treatment changing market dynamics.'
According to the report, one of the major drivers for this market is the presence of a large patient pool of neuropathy pain.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Alfasigma Spa
- Astellas Pharma Inc.
- AstraZeneca Plc
- Baxter International Inc.
- Biogen Inc.
- Bristol Myers Squibb Co.
- Daiichi Sankyo Co. Ltd.
- Dr Reddys Laboratories Ltd.
- Eli Lilly and Co.
- Endo International Plc
- GlaxoSmithKline Plc
- Johnson and Johnson
- Mallinckrodt Plc
- Neuracle Lifesciences Pvt. Ltd.
- Pfizer Inc.
- Sanofi
- Sun Pharmaceutical Industries Ltd.
- Vertex Pharmaceuticals Inc.
- VistaGen Therapeutics Inc.
